Peer-reviewed veterinary case report
Imidapril treatment for congestive heart failure in dogs study
By Besche, B et al.·Published in The Journal of small animal practice·2007·ICON Clinical Research 20, France·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical evaluation of imidapril in congestive heart failure in dogs: results of the EFFIC study.
- Species:
- dog
Plain-English summary
A group of dogs with congestive heart failure, which causes symptoms like coughing, difficulty breathing, and lethargy, were treated with either imidapril or benazepril to see which worked better. After 84 days, both medications showed similar success rates in improving the dogs' heart function and overall health. While some dogs experienced side effects, the rates were comparable between the two treatments. This means that imidapril is a safe and effective option for managing congestive heart failure in dogs, just like the more commonly used benazepril.
People also search for: dog congestive heart failure treatment · imidapril for dogs · benazepril side effects in dogs
Abstract
OBJECTIVES: The clinical efficacy and safety of imidapril were evaluated in dogs that presented with mild to severe congestive heart failure (New York Heart Association stage II to IV) by comparing the success rate of imidapril with a positive control by a non-inferiority approach. METHODS: This good, clinical practice compliant, multicentre study (EFFIC study) enrolled 142 client-owned dogs and was conducted in 20 locations in France, Belgium and Germany. Dogs of various breed, age and weight were included in the study. These dogs were randomised into two groups that were treated for 84 days with either the test product, imidapril, or the positive control, benazepril, and followed up in parallel over this period. Both treatments were administered at a dose of 0.25 mg/kg once a day with the possibility of doubling this dose to 0.5 mg/kg if considered necessary from a clinical point of view. In addition, concomitant treatment was given to dogs presenting with pulmonary oedema and/or ascites, supraventricular tachyarrhythmia and/or dilated cardiomyopathy. The evolution of the New York Heart Association stage and the "functional signs" score were evaluated as primary efficacy criteria. RESULTS: The success rate in the imidapril group was 66 compared with 68 per cent in the benazepril group. Regarding safety, 35 dogs in each group experienced at least one adverse event. Nine dogs in each group experienced at least one serious adverse event. The difference between these results was not statistically significant. CLINICAL SIGNIFICANCE: Imidapril is as efficacious and safe as the reference product, benazepril.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17472664/